A Proactive Approach to Detecting Cancer: Penn State Health St. Joseph Cancer Center’s Cancer Risk Evaluation Program

Penn State Health St. Joseph Cancer Center uses genetic evaluation to determine patients’ cancer risk and provide actionable next steps through their Cancer Risk Evaluation Program (CREP).

Penn State Cancer Institute Researchers Promote Personalized Colorectal Cancer Screening in Central Pennsylvania

Colorectal cancer is the second-leading cause of cancer death in central Pennsylvania, which is partially attributable to low screening rates among certain segments of the population. Penn State Cancer Institute researchers are developing and testing strategies to improve screening rates in order to diagnose and treat colorectal cancer in earlier stages, when treatment efficacy is generally optimized.

Penn State Health Medical Group — Andrews Patel Hematology/Oncology: Greater Collaboration in Cancer Care Benefits Patients

Andrews Patel Hematology/Oncology has been providing central Pennsylvania residents access to high-level cancer care for more than 30 years and is now doing even more as part of Penn State Health.

Leading Role in Clinical Trial Positions Hershey Medical Center in Vanguard of Urological Care

Penn State Health Milton S. Hershey Medical Center is one of eight academic medical centers nationwide taking part in a clinical trial of Cxbladder — a noninvasive test that could spare thousands of patients the pain and expense involved in evaluating a diagnosis of hematuria.

Penn State Health Tests Novel, Nonsurgical Therapy for Common Form of Bladder Cancer

Patients with a noninvasive, low-grade form of bladder cancer often need multiple surgeries to treat recurrences, which are common. A new chemoablative gel currently under study at Penn State Health may eliminate the need for those procedures.

Penn State Health St. Joseph Cancer Center Brings Advanced Technology and High-Level Care to Berks County

The newly renovated Penn State Health St. Joseph Cancer Center in Bern Township delivers innovative oncology services and state-of-the-art technology to area patients so they can receive virtually the entire spectrum of cancer care without the burden of long commutes.

Expanded Clinical Trials at Penn State Cancer Institute Boost Area Patients’ Access to Leading-Edge Care

With a significant expansion of researcher-driven clinical trials and a sharp focus on the region’s distinct healthcare needs, Penn State Cancer Institute (PSCI) is bringing the latest in cancer treatments to central Pennsylvania.

Hershey Medical Center Achieves More Accurate Prostate Cancer Diagnosis with MRI-Guided Fusion Biopsy

Merging the capabilities of MRI and ultrasound technology in real time, Penn State Health Milton S. Hershey Medical Center uses MRI-guided fusion biopsy to more accurately detect the presence and aggressiveness of prostate cancer. This innovative technique facilitates accurate prostate cancer diagnosis while reducing the possibility of nondiagnostic biopsies and the need for repeat procedures.

Groundbreaking CAR-T Cell Therapy Arrives at Penn State Cancer Institute

Penn State Cancer Institute is the first and only healthcare facility in central Pennsylvania to offer the leading-edge treatment CAR-T cell (CAR-T) therapy to adult patients with lymphoma who have exhausted all other options. Kite Pharma, a division of Gilead, chose just a handful of U.S. facilities for its rollout of the potentially lifesaving treatment, Yescarta, which uses gene editing to boost patients’ own T cells against their cancer.

Setting the Standard for Exercise Oncology

Cancer treatment summons to mind images of patients passively undergoing chemotherapy or radiation treatment, not actively participating in a program of exercise to alleviate symptoms and enhance outcomes.